ArticleAging2024
Metabolic score for insulin resistance predicts major adverse cardiovascular event in premature coronary artery disease.
Article in Aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Does diabetes status modify the association between the triglyceride-glucose index and major adverse cardiovascular events in patients with coronary heart disease? A systematic review and meta-analysis of longitudinal cohort studies.Cardiovascular diabetology · 2025Pooled it
- Association of the Triglyceride-Glucose Index with Premature Myocardial Infarction in a Propensity Score-Matched Non-Diabetic Population.Diagnostics (Basel, Switzerland) · 2026Article
- Association between METS-IR and incident stroke in a nationwide prospective cohort of non-diabetic Chinese adults.BMC neurology · 2026Article
- Metabolic score for insulin resistance is associated with adverse cardiovascular events in patients with type 2 diabetes.World journal of diabetes · 2025Article
- Article
- Evaluating the impact of metabolic indicators and scores on cardiovascular events using machine learning.Diabetology & metabolic syndrome · 2025Article
- Article
- Characterisation of cardiovascular disease (CVD) incidence and machine learning risk prediction in middle-aged and elderly populations: data from the China health and retirement longitudinal study (CHARLS).BMC public health · 2025Article
- Article
- Metabolic score for insulin resistance as a predictor of mortality in heart failure with preserved ejection fraction: results from a multicenter cohort study.Diabetology & metabolic syndrome · 2024Article
- Association between metabolic score for insulin resistance and stroke: a nationally representative cross-sectional study from NHANES 2007-2018.Frontiers in neurology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Metabolic Score for Insulin Resistance (METS-IR) index serves as a simple surrogate marker for insulin resistance (IR) and is associated with the presence and severity of coronary artery disease (CAD). However, the prognostic significance of METS-IR in patients with premature CAD remains unclear. This study aims to investigate the prognostic value of METS-IR in premature CAD.
methodsThis retrospective study included 582 patients diagnosed with premature CAD between December 2012 and July 2019. The median follow-up duration was 63 months (interquartile range, 44-81 months). The primary endpoint was Major Adverse Cardiovascular Events (MACE), defined as a composite of all-cause death, non-fatal myocardial infarction (MI), repeat coronary artery revascularization, and non-fatal stroke.
resultsPatients with MACE had significantly higher METS-IR levels than those without MACE (44.88±8.11 vs. 41.68±6.87,
conclusionsMETS-IR serves as a reliable prognostic predictor of MACE in patients with premature CAD. Therefore, METS-IR may be considered a novel, cost-effective, and dependable indicator for risk stratification and early intervention in premature CAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.